The Herpes simplex virus 1 (HSV) thymidine kinase (tk) suicide gene together with ganciclovir (GCV) have been successfully used for the in vivo treatment of various solid tumors and for the ablation of unwanted transfused stem cells in recent clinical trials. With the aim of improving this therapeutic system, we compared the potential efficacy of adenoviral (Ad) vectors expressing enhanced tk mutants in vitro and in vivo. The previously created HSV-tk mutants dm30 and sr39, created by random sequence mutagenesis, were inserted into a standard Ad.RSV E1 À
S
uicide gene therapy, one of several gene therapeutic approaches to treat cancer, was proposed in 1986 by Moolten. 1 A suicide gene encodes a protein, frequently an enzyme, that in itself is nontoxic to the genetically modified cell. However, when a cell is exposed to a specific nontoxic prodrug, the prodrug is selectively converted by the gene product into toxic metabolites that kill the cell. The suicide gene most commonly employed, both in experimental and clinical settings, is the Herpes simplex virus type 1 thymidine kinase (HSV-tk), which encodes an enzyme that is able to phosphorylate the prodrugs ganciclovir (GCV) or acyclovir (ACV) into toxic forms that lead to cell killing. 2 In addition to killing the transduced cells, an important feature of this system is an indirect or 'bystander' effect where other, nontransduced tumor cells are also killed. 3 The applicability of the HSV-tk/GCV approach in cancer therapy was first demonstrated in 1992 by Culver et al 2 who documented the regression of brain tumors in rats by injection of retrovirus producer cells expressing HSV-tk, which then transduced the surrounding tumor tissue followed by treatment with GCV. Since that time, HSV-tk suicide gene therapy has been employed in many experimental and clinical settings, 4 including treatment of localized tumors, [5] [6] [7] [8] restenosis, 9 graft-versus-host disease, 10 and HIV infections. 11 Based on encouraging preclinical data, clinical trials were aimed at treating brain tumors by injecting retroviral HSV-tk producer cells. A number of clinical studies, including a large Phase 3 trial, 12 showed this approach was safe, but had limited efficacy. Given the limitations of retroviral vectors in in vivo settings, gene transfer experiments using HSV-tk encoded by adenoviral vectors were developed. Since the original report of an effective Ad.HSV-tk vector, 13 this approach has been used extensively in many animal models and in clinical trials of malignant diseases such as malignant mesothelioma, 6, [14] [15] [16] [17] brain tumors, [18] [19] [20] ovarian carcinoma, 21, 22 prostate cancer, 23, 24 and melanoma. 25 In general, these studies have shown that the approach is well tolerated and, when examined, that there has been clear evidence of gene transfer. Despite the fact that these have been Phase 1 trials, there have been some intriguing hints of efficacy. For example, in our Ad.HSVtk/GCV intrapleural mesothelioma trial, 6 complete tumor regression, associated with long-term (44.5 years) survival was observed in two patients (unpublished data). However, the limited clinical responses seen in the majority of patients highlight the major limitation of this approach: suboptimal efficiency of gene transfer.
There are a number of approaches that have been taken to improve transgene delivery. One strategy, not discussed here, is to improve the vector itself, for example, by creating replicating vectors. 26 A second approach involves enhanced targeting of the vectors. 27 A third approach is to develop transgenes with enhanced tumor killing characteristics that can be delivered with existing vectors. Thus, novel HSV-tk's with increased specificity for phosphorylating GCV and ACV could enhance tumor cell killing, lower the effective dosage of GCV, or allow the use of the less toxic prodrug ACV in place of GCV. With this aim in mind, Black et al 28, 29 created a series of drug-specific HSV-tk mutants using random 28 and semirandom 29 sequence mutagenesis. A number of mutants rendered cells more sensitive to both GCV and ACV when tested in vitro. Two of these mutants, termed dm30-tk and sr39-tk, have been studied in detail by stable transfection into various tumor cell lines followed by testing in cell culture and animal models. [28] [29] [30] [31] [32] [33] These studies demonstrated that cells infected with either of the mutant enzymes showed enhanced sensitivity to GCV and ACV when compared to cells transduced with wild-type HSV-tk.
These results using stably infected tumor cell lines suggested the hypothesis that enhanced HSV-tk mutants could potentially be efficacious in the more clinically useful setting of adenovirally mediated gene transfer. Accordingly, the HSV-tk mutants, dm30-tk and sr39-tk, were inserted into a standard Ad.RSV E1 À E3 À backbone for use in comparison to the wild-type Ad.HSV-tk in both in vitro and in vivo models.
Methods

Cell lines and materials
REN and LRK cells are human mesothelioma cell lines isolated in our laboratory from patients' tumor specimens. 13 I-45 is a human mesothelioma cell line obtained as a gift from Dr Joe Testa (Fox Chase Institute, Philadelphia, PA). H2052 and H513 are human mesothelioma cell lines originated from pleural effusion from the American Type Culture Collection (ATCC, Manassas, VA; www.atcc.org). A549 is a human nonsmall cell lung cancer and C-33A human cervical cancer cell line purchased from the ATCC. All above-mentioned cell lines were cultured and maintained in RPMI medium with 10% fetal calf serum (FCS; Georgia Biotechnology, Atlanta, GA). The EJ62 line (EJ-6-2-Bam-6a) is a 3T3 mouse fibroblast cell line transformed with the h-ras oncogene that forms tumors in Balb/c mice, which was purchased from the ATCC and maintained in high glucose Dulbecco's modified Eagle's medium (DMEM; Mediatech, Washington, DC) plus 10% FCS. Rat C6 glioma cells were purchased from ATCC and maintained in DMEM with 10% FCS. Media for all cell lines were supplemented with 2 mM l-glutamine and 1% penicillin (100 U/ml) and streptomycin (100 mg/ml). All cell culture media were from GibcoBRL (Invitrogen Life Technologies, Carlsbad, CA), cell culture supplies were from Becton Dickinson Labware (Franklin Lakes, NJ). Unless otherwise specified, reagents were purchased from Sigma (St Louis, MO).
Thymidine kinase mutants
Two libraries of Herpes simplex type I (HSV1) thymidine kinase (tk) mutants were generated by Black et al 28, 29 by random sequence mutagenesis by targeting codons encoding Leu-159, Ile-160, Phe-161, Ala-168, Leu-169, and Leu-170 with the codon for Leu-170 omitted from one of the library constructions as described earlier. pET23d (Novagen, Madison, WI) served as vector backbone for the construction of pET23d:HSV1tk-dummy vector, which was used for construction of the library and for protein overexpression. The DNA constructs pET23d:HSV1tk, pET23d:dm30, 28 and pET23d:sr39 29 were used to create shuttle vectors for adenoviral preparation.
Recombinant adenovirus constructs
To construct the replication-incompetent adenoviruses containing the wild-type or mutant tk's, approximately 1.13 kb full length tk cDNA was amplified by PCR from pET23d:HSV1tk, pET23d:dm30, 28 and pET23d:sr39 29 using the forward (5 0 -attaggatcctccaccatggcttcgtaccccggccat-3 0 ) and reverse (5 0 -aattggatcctcagttagcctcccccatct-3 0 ) primers engineered to include BamH1 sites at the 5 0 ends. The PCR product was digested with BamH1 and subcloned into the BamH1 site of the pAd.RSV.Link plasmid. 34 The orientation of the tk gene with respect to the RSV promoter was confirmed by nucleotide sequencing. The pAd.RSV.Link plasmid was co-infected with Cla1 digested and E3 deleted adenovirus type 5 DNA into 293 cells as a calcium phosphate precipitate as described earlier. 34 Cells were overlaid with agar and when plaques appeared, individual plaques were analyzed for the presence of the transgene by Western blot. Two positive virus clones were subjected to three rounds of plaque purification on 293 cells and one clone was processed for large-scale preparation and purified twice by ultracentrifugation on cesium chloride gradients. We verified the correct nucleotide sequence of the transgene in all viruses by sequencing the entire 1.130 kb of the tk-cDNA from both the 5 0 and 3 0 ends (data not shown). The concentration of the viral particles was determined by measuring the absorbance at 260 nm. Serial dilutions of the virus were plated on 293 cells for plaque assay and the titer was expressed as plaque forming units (PFU)/ml. The particle to PFU ratio of each preparation was determined in 293 cells and ranged between 20:1 and 100:1. Vector preparations were shown to be negative for the presence of wildtype adenovirus. Ad.RSV E1 À E3 À dm30-tk and Ad.RSV E1 À E3 À sr39-tk are named Ad.dm30-tk and Ad.sr39-tk, respectively.
As a control vector, replication-deficient adenoviral vector encoding the HSV-tk gene driven by the Rous Sarcoma virus 3 0 promoter region was used, 13, 35 and was provided by the Vector Core of the Institute for Human Gene Therapy of the University of Pennsylvania Health System. The adenoviral vector Ad.RSV E1 À E3 À HSV-tk is referred to as Ad.HSV-tk. As abbreviation for thymidine kinase, tk is used for the gene and TK is used for the protein.
Immunohistochemistry and immunoblot analysis
For initial in vitro experiments, REN, C6, A549, and SKOV3 cell lines were plated and grown to subconfluence in T25-flasks, counted, and were infected with varying multiplicities of infection (MOI) of adenovirus per cell) with Ad.HSV-tk, Ad.dm30-tk, and Ad.sr39-tk. Flasks were then incubated at 371C and 5% CO 2 for 4 hours, after which the viral suspension was removed and replaced with fresh media for 2 hours for cell recovery. Cells were then transferred into 24-well plates for immunohistochemistry, or into six-well plates for immunoblot analysis and incubated for another 48 hours. Cells subjected to survival studies in the presence of prodrug were transferred to 96-well plates, using our in vitro Prodrug Sensitivity Assay protocol (see below).
For immunohistochemistry, monolayers were fixed with 2% paraformaldehyde, permeabilized with 0.1% Triton X-100, and incubated with a polyclonal rabbit anti-HSV-TK antibody 13 as primary antibody and biotinylated mouse anti-rabbit IgG (Vectastain, Vector Laboratories, Inc., Burlingame, CA) or biotinylated control IgG as secondary antibodies. Visualization was achieved by the use of Vectastain kit ABC Elite kit or by Alkaline Phosphatase kit (both Vector Laboratories) using the manufacturer's protocols.
To measure the TK protein levels, cell lysates were prepared as described. 36 Briefly, infected cells were placed on ice, washed in ice-cold PBS, incubated 10 minutes with lysis buffer (2% SDS, 0.125 M Tris-HCl pH 6.8), scraped, DNA sheared with multiple pipetting, and pelleted. Supernatant was collected and total protein concentration was measured using the BCA protein assay kit (Pierce, Rockford, IL). A measure of 10 mg of the total cell extract was separated on 10% SDS-polyacrylamide reducing gel (Invitrogen) and electro-blotted onto PVDF (NEN Life Sciences, Boston, MA) membrane as per the manufacturer's instructions. The blot was blocked in 5% milk in TBS-T (10 mM Tris-HCl, 150 mM NaCl, and 0. 
Comparison of TK-expression level
In order to compare the in vitro prodrug sensitivity based on the equal amounts of HSV-TK, dm30-TK, and sr39-TK protein expressed for a given cell line, we performed several plaque assays for each virus to accurately determine the particle to PFU ratio. We adjusted the number of viral particles so that equivalent MOIs of virus were added and then performed immunoblot analysis of TK protein expression to ensure relatively equal infection levels. For every in vitro sensitivity assay performed, we also did an immunoblot analysis of TK protein expression on a duplicate plate to ensure equal infection levels. Although each cell line required a different MOI because of different levels of infectivity, the same MOI of each virus was used for each cell line.
In vitro prodrug sensitivity assay
To evaluate and compare the direct antiproliferative effect among the three tk viruses on the various cell lines, cells were infected in parallel with 'wild-type' Ad.HSV-tk, Ad.dm30-tk, and Ad.sr39-tk at various concentrations. Generally, after selecting the appropriate MOIs in pretests, three different MOIs were selected for each cell line (e.g., for C6 cells MOIs of 4, 20, and 80 were used). Cells were infected in T25-flasks and, following the incubation and recovery periods (see above) were seeded in quadruplet in 96-well plates (100 ml media/well) at a density of 2 Â 10 3 cells per well (fast growing cell lines, i.e., C6 cells) to 1 Â 10 4 cells per well (slow growing cells, i.e., H2052). After a 24 hour incubation period, 20 ml of medium was added containing varying concentrations of prodrug (0-3000 mM). Cells were refed on a daily basis with medium containing prodrug up to day 5. Survival of infected cells compared with uninfected cells was measured when uninfected cells reached confluency (usually after 5-8 days after infection) using the MTS assay, which is a colorimetric test for the quantitation of cell viability and proliferation (Cell Titer 96 TM Aqueous Nonradioactive MTT Cell Proliferation Assay; Promega Corporation, Madison, WI). The percentage of inhibition of cell growth was calculated according to the following formula:
Inhibitionð%Þ ¼ ð1 À A 490 of treated group=A 490 of control groupÞ Â 100
Experimental animals
Female BALB/C and female CB17-SCID mice (6-8 weeks old; weight, B20-25 g) were obtained from Taconic Laboratory (Germantown, NY) and Wistar Institute (Philadelphia, PA), respectively. Animals were housed in the animal facility at the Wistar Institute (Philadelphia, PA). All mice were maintained in a pathogen-free animal facility for at least 10 days before each experiment. The Animal Use Committees of the Wistar Institute and University of Pennsylvania approved all protocols in compliance with the Guide for the Care and Use of Laboratory Animals.
In vivo Flank tumor studies using pre-transduced cells
Flank tumor studies using pretransduced cells were carried out in immune-competent (EJ62 in Balb/C mice) and immune-incompetent (C6 glioma and I-45 human mesothelioma cells in SCID mice) animals. Preliminary studies showed that mixtures of 5% cells pretransduced with Ad.HSV-tk with 95% nontransduced tumors resulted in a moderate degree of tumor growth inhibition appropriate to evaluate enhanced effects with the mutant vectors.
Tumor cells were infected as described above with each of the three vectors (the chosen MOI was based on the in vitro data and assured a high TK expression without cell death). After overnight incubation, cells were harvested as usual using 0.05% trypsin-Versene (Life technologies; Grand Island, NY), pelleted (1000 rpm, 3 minutes), washed a second time in PBS, resuspended at 2.5 Â 10 6 cells/ml in serum-free DMEM, and mixed with nontransduced cells for injection. A total of 5 Â 10 5 cells (200 ml) were injected subcutaneously (s.c.) bilaterally into shaved mice flanks. Immunoblot analysis indicated an equivalent TK expression level among the cells infected with the three versions of Ad.tk's. The following day, mice were randomized for prodrug treatment versus control (n ¼ 10-12 tumors each group). Intraperitoneal (i.p.) treatment with GCV (50 mg/kg/animal) 26 or saline control once daily was initiated for 5 days. Tumor size was determined by caliper measurements at various intervals on average every 3-5 days. Tumor volume was computed using the formula for the volume of an ellipsoid, 0.5LW 2 , where L is the length ( ¼ longest diameter) of the tumor and W is the width of the tumor.
Treatment of established flank tumors
Flank tumors with I-45 or C6 cells were established by injecting 5 Â 10 5 cells s.c. into flanks of SCID mice. In the first experiment with C6 flank tumors, when mean tumor volume had reached approximately 50 mm 3 at Day 7, the mice were randomized into the following treatment groups (n ¼ 10 tumors/group): (1) media control, (2) Ad.HSV-tk, (3) Ad.dm30-tk, and (4) Ad.sr39-tk. Tumors were injected once intratumorally with media or vector at a dose of 1 Â 10 9 PFU in a total volume of 50 ml serumfree media. Starting on Day 9, all animals were treated with i.p GCV (50 mg/kg/animal) once daily for 5 days. Tumor size was determined by caliper measurements on average every 5 days.
The same model was used to examine the effect of instillation of the Ad.tk vectors in bulkier C6 flank tumors. We staggered the time of vector instillation to allow the animals to develop larger tumor volume of 200-250 mm 3 s.c. nodules. At Day 14, mice (n ¼ 10 tumors/ group) received a single intratumoral injection of 1 Â 10 9 PFU of either media alone, Ad.HSV-tk, Ad.dm30-tk, and Ad.sr39-tk (n ¼ 20 tumors). Starting on Day 16, animals were treated with i.p. GCV (50 mg/kg/ animal) once daily for 5 days except for half of the animals injected with Ad.sr39-tk, who did not receive GCV. This group served as an additional control to monitor for unspecific adenoviral effects on tumor growth.
For treatment of I-45 flank tumors, mice, randomized as described above, were injected when the mean tumor volume had reached approximately 100 mm 3 at Day 10, and given i.p. GCV treatment with 50 mg/kg/animal once daily for 5 days starting on Day 12. Follow-up was performed as described above.
Statistics
Results are expressed as the mean7SEM. We have performed cross-sectional analyses of difference at each time point (in vivo studies) to supplement descriptive analysis and plots. Differences in in vitro inhibition results, and tumor volumes in the animal experiments were determined by one-way analysis of variance (ANO-VA) adapted for multiple comparisons (Tukey-Kramer test) (JMP s ; SAS Institute Inc., Cary, NC) and Repeated Measures ANOVA (JMP s ). Statistical significance was set at Po.05, if not otherwise mentioned.
Results
Characterization of mutant HSV-TK vectors
Based on previous studies, [28] [29] [30] [31] [32] two mutants with enhanced sensitivity to GCV and/or ACV, dm30-tk and sr39-tk, were selected for insertion into adenoviral vectors. As previously described, 29 mutations in residues just N-terminal to these motifs (residues 159-161 and 168-170) resulted in enzymes with enhanced activity, presumably because these regions participate in nucleoside binding, perhaps molding the overall binding pocket structure and/or to maintaining the hydrophobicity of the active-site cavity. [28] [29] [30] 32, 37 Based on these favorable characteristics, each of the mutant genes was cloned into a replication-deficient E1/ E3-deleted adenoviral vector using the Rous sarcoma virus (RSV) promoter. The vectors were called Ad.HSVtk, Ad.dm30-tk, and Ad.sr39-tk. After creation of the adenoviral vectors, sequence analysis of the two mutants confirmed that each contained the appropriate five amino-acid substitutions within the randomized region.
Production of HSV-TK enzymes was first assessed by immunohistochemistry. All cell lines showed an identical immunohistochemical TK-staining pattern, with TK expression primarily in the nucleus with some cytoplasmic staining in cells with higher expression (data not shown). Uptake was somewhat patchy at lower MOIs. Staining of either uninfected control cells or of infected cells with control antibodies was negative.
Protein expression was quantitated by immunoblotting of cell lysates (10 mg protein in each sample) to allow for direct comparison. A 44 kD band representing the TK protein was identified in each cell line and with each virus. As would be expected, the efficiency of infection and protein production varied markedly among cell lines (data not shown).
In order to accurately compare vectors with one another, it was necessary to make sure that the amount of cellular TK protein was similar for each vector. We performed several plaque assays for each virus and based on that information, we calculated the plaque to PFU ratio. We then infected each cell line with equivalent PFU and ensured that the protein levels for the mutant TKs were equal to (or slightly lower than) the wild-type HSV-TK level using immoblot assays. Thus, for every cell line tested, we varied the absolute MOIs, but kept the relative titers of the different vectors the same. We verified similar protein expression levels by immunoblot for every cell survival experiment in every cell line we tested. A representative immunoblot for I-45 human mesothelioma cells at two different MOIs is shown in Figure 1 .
In vitro prodrug sensitivity assay
To compare the efficacy of prodrug-mediated cell killing of Ad.HSV-tk with Ad.dm30-tk and Ad.sr39-tk, a total of nine cell lines were infected at various MOIs and exposed to varying doses of GCV (or in some cases ACV) continuously for at least 5 days. Figure 2 shows an example of sensitivity curves in C6 cells (Fig 2a and b) and REN cells (Fig 2c) with varying doses of Ad.sr39-tk and varying doses of GCV (Fig 2a and c) or ACV (Fig 2b) . Each virus/prodrug combination was able to enhance cell killing in a clear dose-responsive fashion. Interestingly, although the C6 cells were less sensitive to infection than REN cells, the C6 line was more sensitive to the killing effects of HSV-tk plus GCV illustrating that other factors in addition to the amount of HSV-TK enzyme contribute to the sensitivity of a cell line to killing. One possible explanation might be that C6 cells have a higher DNA synthesis rate than REN cells rendering them more sensitive to toxic effects. The IC 50 levels listed for Ad.HSV-tk are representative for a high tk expression level at the MOI reported (shown in parentheses), and vary by the factor of B2000. The adenovirus-mediated transfer of dm30-tk and sr39-tk improves prodrug-mediated tumor cell killing compared to HSV-tk on an average of two-three fold. Data represent mean7SEM of n=3 (H513, C33A, EJ62,), n=4 (H2052, A549), n=9 (C6, I-45, LRK), and n=14 (REN) independent experiments with equal TK level of expression as assessed by densitometry (MOI's may vary). The * indicates statistical significance at the Po.05 level in comparison to HSV-TK (one way ANOVA for multiple comparisons).
Gene transfer of Ad.HSV-tk mutants R Wiewrodt et al
Figures 2d-f shows the killing curves derived from direct comparisons of the three Ad vectors administered at equivalent MOIs. A comparison of the killing curves shows that in every case, at a given dose of GCV (Fig 2d  and f) or ACV (Fig 2e) there was enhanced killing with the mutant HSV-TK's. This increased efficacy was quantified by computing the IC 50 dose of GCV or ACV, that is, the dose of drug that results in 50% of the cells being killed. A lower IC 50 represents a more efficient enzyme. For example, in this experiment, the IC 50 s in REN cells for Ad.HSV-tk, Ad.dm30-tk, and Ad.sr39-tk are 0.6, 0.2, and 0.08 mM indicating that sr39 is Figure 2 Comparison of prodrug dose-response cell survival curves in C6 glioma cells and REN human mesothelioma cells. In panels a-c, the survival of C6 cells (a, b) or REN cells (c) infected with Ad.sr39-tk at different MOIs exposed to a range of GCV (a, c) or ACV (b) concentrations was compared to uninfected cells. A clear dose-response was noted. In Panels d-f, cells were infected with equivalent doses of Ad.sr39-tk, Ad.dm30-tk, and wild-type Ad.HSV-tk and exposed to a range of GCV concentrations (panels d and f) or ACV concentrations (panel e). Points on the ordinate correspond to the ratio of living C6 (a, b, d and e) cells and REN cells (c, f) present at each dose compared to cells treated with no prodrug. Graphs shown represent a single experiment, in which each data point was calculated as mean7SEM of quadruplets on the same plate. Each experiment was repeated at least three times with similar results.
Gene transfer of Ad.HSV-tk mutants R Wiewrodt et al approximately 7.5 times more efficient that HSV-tk. In C6 cells, an even larger difference among the mutants is seen after exposure to ACV. As shown in Figure 2e , the IC 50 for ACV is 3 mM for Ad.HSV-tk, 0.6 mM for Ad.dm30-tk, and 0.15 mM for Ad.sr39-tk, a 20-fold difference. Although we focused on the TK/GCV system in this study, these mutants may also be useful if ACV is used as a prodrug (i.e. see Pantuck et al 33 ). To compare the efficacy of prodrug-mediated cell killing of Ad.HSV-tk, Ad.dm30-tk, and Ad.sr39-tk, a total of nine human, rat, and mouse cell lines were infected at various MOIs and exposed to varying doses of GCV continuously for at least 5 days. Table 1 shows summary data from a large number of these experiments. There is a wide variation in the sensitivity of each cell line to killing by Ad.HSV-tk with IC 50 s ranging from 0.6 to 230 mM. However, vectors expressing mutant TKs consistently showed IC 50 s that were two to three-fold lower than that of the wild-type Ad.HSV-tk virus (range: 1.1 to 5.9-fold improvement). The changes in mutant enzyme efficacy were statistically significant in 14 of 18 comparisons to wild-type TK. The average improvement (2.6-fold) seen with Ad.sr39-tk was slightly better than that seen with Ad.dm30-tk (2.3-fold); however, in some cell lines Ad.dm30-tk performed better than Ad.sr-39-tk. 
In vivo mixing flank tumor studies
To define and compare the in vivo efficacy of the adenoviral vectors carrying wild-type and mutant tk's and to analyze improvements in bystander effect, subcutaneous pretransduced tumors were established in three animal tumor models: SCID mice injected with C6 cells rat glioma cells (Fig 3a and b) , SCID mice injected with I-45 human mesothelioma cells (Fig 3c and d) , and BALB/C mice injected with syngeneic EJ62 transformed fibroblasts (Fig 3e and f) . Cells were infected in vitro with Ad.HSV-tk, Ad.dm30-tk, and Ad.sr39-tk. Bilateral flanks were injected with a 5 Â 10 5 cell mixture of 5% infected/ 95% untransduced cells. On Day 1 after tumor injection (Day 2 after infection), mice were randomized and treated either with intraperitoneal GCV or saline for five consecutive days. Tumor volumes were regularly measured.
As shown in Figure 3 , there were significant differences in the size of tumors in mice treated with GCV versus saline in all flank tumor models tested (Fig 3a,c and e) . A 5% mixture of tk-infected cells for any of the tk construct was not sufficient to abolish tumor growth; however, tumor growth was significantly slowed down compared to animals that did not receive the prodrug.
In all three models, however, the cells transduced with the mutant tk genes grew more slowly than cells transduced with HSV-tk (Fig 3) . To compare the tumor killing effect of tumors expressing HSV-tk and the mutants dm30-tk and sr39-tk in parallel, we calculated the ratio of tumor volumes of saline-treated control animals to those of GCV-treated tumors for the three TK proteins tested (Fig 3b, d and f) . In every case and at every time point, prodrug-treated tumors containing HSV-tkinfected cells were larger than tumors containing cells infected with either of the mutant tk's (Po.05, ANOVA). In the C6 model, the tumor size averaged three to fivefold lower for the tk mutants than HSV-tk-transduced tumors (Fig 3b) . In the I-45 model, differences between HSV-tk and mutant tk tumor growth diminished over time (Fig 3d) , whereas the EJ62 model showed an opposite tendency (Fig 3f) . Statistical analysis showed there were significant differences between wild-type tk transduced tumors and the tumors transduced with the mutants sr39-tk and dm30-tk (Po.05, all comparisons, ANOVA). Since the tumors contained only 5% transduced cells, these experiments show enhanced bystander effects in cells transduced with the mutant tk's versus wildtype tk.
Treatment of established flank tumors with a single intratumoral administration of various Ad.TKs
To compare the efficacy of the adenoviral vectors expressing wild-type and mutant tk's in an in vivo model closer to one that might be used clinically, subcutaneous tumors were established in the flanks of SCID mice using the C6 cells rat glioma cell line (Fig 4a and b) and I-45 human mesothelioma cell line (Fig 4c) . In the first experiment, C6 cells were injected into the flanks of SCID mice and allowed to grow for 1 week into palpable tumors. On Day 7, the tumors were injected with media alone or one of the three tk vectors, followed by 5 days of intraperitoneal GCV at 50 mg/kg (Fig 4a) . This dose of GCV was chosen as one that is effective but minimally toxic to the animals. Tumor growth in the Ad.HSV-tk-treated group Figure 4 Treatment of established glioma and mesothelioma flank tumors with a single intratumoral administration of various Ad.tk's. SCID mice were injected with C6 rat glioma cells (a, b) and I-45 human mesothelioma cells (c) to establish subcutaneous flank tumors. At various days (arrow), the mice were randomized into the following treatment groups (n ¼ 10 tumors/group): (1) media control, (2) Ad.HSV-tk, (3) Ad.dm30-tk, and (4) Ad.sr39-tk, and received an intratumoral injection of 1 Â 10 9 PFU vector in serum-free media or media control. After 2 days, animals were treated with i.p. ganciclovir (50 mg/kg/animal) once daily for 5 days. Tumor size was determined by caliper measurements and tumor volume was calculated. The data represent single experiments. The * indicates statistical significance at the Po.05 level of Ad.mutant-tk-treated animals in comparison to control animals, all of which received GCV (one way ANOVA for multiple comparisons). Error bars represent SEM.
was compared with media alone, Ad.dm30-tk and Ad.sr39-tk. As shown in Figure 4a , there was no significant difference in mice treated with media alone versus Ad.HSV-tk+GCV. However, both tk mutants showed a significantly lower tumor growth versus media, and tumor volumes after transduction with mutant sr39-tk were even significantly lower when compared to tumors transduced with mutant dm30-tk (Po.05, ANOVA, all comparisons).
In a second experiment, C6 cells were injected into the flanks of SCID mice and allowed to grow to a larger size. On Day 14, the tumors were injected with media alone or one of the three tk vectors. Three groups of animals received 5 days of intraperitoneal GCV. An additional control group was injected with Ad.sr39-tk but did not receive GCV treatment. The results are shown in Figure 4b . Animals injected with Ad.sr39-tk without GCV showed almost identical tumor growth compared to animals that were injected with media, demonstrating that Ad.sr39-tk by itself had no unspecific antitumoral effect. Only small effects were seen in the Ad.HSV-tk/GCV group. In contrast, both Ad.sr39-tk and Ad.dm30-tk markedly decreased tumor growth (Po.05, ANOVA). No significant differences between tumors injected with Ad.dm30-tk versus Ad.sr39-tk were observed in this model.
Finally, the effect of each vector was also tested in a model of human tumor growing in SCID mice (Fig 4c) . I-45 mesothelioma cells were injected into the flanks of SCID mice and tumors allowed to form. On Day 7, the tumors were injected with media alone or one of the three tk vectors, followed by 5 days of intraperitoneal GCV. Tumor growth in the Ad.HSV-tk-treated group was compared with media alone, Ad.dm30-tk and Ad.sr39-tk. There was a small, but not statistically significant, difference in mice treated with media alone versus Ad.HSV-tk+GCV. However, tumors injected with either tk mutant showed a significant lower growth rate versus tumors injected with media, and there was also a significant difference between mutant sr39-tk and HSVtk (Po.05, ANOVA). There is no statistically significant difference when mutant sr39-tk was compared to mutant dm30-tk.
Discussion
The goal of this paper was to test the hypothesis that adenoviruses containing HSV-tk mutants with enhanced selectivity would be more effective than wild-type HSV-TK in a therapeutic treatment strategy. To accomplish this goal, we first cloned the mutant TK genes into the same 'first generation' adenoviral backbone, using an RSV promoter and took great care in making sure that HSV-tk expression levels were similar after infection with each vector (Fig 1) so that accurate comparisons could be made.
Our study using adenoviral vectors clearly showed that the vectors containing mutant tk vectors were more effective in killing cells in vitro; however, the magnitude of in vitro differences between wild-type TK and the mutants (i.e. two to three-fold decreases in IC 50 ) was smaller than the predicted difference in the ratio of specificity constants of HSV-TK to mutant TKs, where mutant tks theoretically should demonstrate a 67-fold (dm30-TK) and 78-fold (sr39-TK) higher sensitivity towards GCV, respectively. The differences in IC 50 s were also much smaller than those reported previously in permanently infected cells where, for example, in C6 cells Kokoris et al 30 reported a 3-4 log decrease in IC 50 when comparing dm30-tk-infected cells with wild-type tkinfected cells and Black et al 29 reported an approximately 300-fold lower IC 50 in cells transduced with sr39-tk versus wild-type tk while our decrease was five-fold in C6 cells. There are a number of possible reasons for these differences. First, it is important to note that for some reason, in our study, C6 cells transduced with wild-type Ad.HSV-tk, at moderate MOIs, had much lower IC 50 s (0.1-0.5 mM of GCV) compared with the stably infected C6 cells (IC 50 values of 5-30 mM). The IC 50 values of the cells transduced with the mutant Ad.HSV-tk's were actually very similar (0.1 mM) to those reported for C6 cells stably transduced with dm30-tk (0.03 mM) and sr39-tk (0.04 mM). This enhanced efficiency of the wild-type TK markedly decreased our augmentation of sensitivity. Second, in our study, expression levels of the three TK enzymes were closely matched. In previous studies, mutant cells had up to a two to four fold (dm30-TK) to 16-fold higher expression level of sr39-TK compared to HSV-TK in stably infected C6 cells. 29, 32 Although there is some controversy about whether the amount of TK enzyme above a certain threshold affects killing abilities, having different levels of enzyme certainly makes comparison more difficult. Finally, there are likely differences in our studies where adenoviral infection does not lead to uniform gene transduction in each cell (data not shown), as compared to retroviral or traditional infection techniques where cells are cultured in selective media. Our in vitro results were actually similar to those recently reported by Pantuck et al 33 using Ad.CMV-TK wild-type and mutant vectors.
We next studied the relative efficiencies of the Ad.tk vectors in animal models of tumor killing that relied on bystander effects. We injected mixtures of cells containing only 5% preinfected/95% nontransduced cells. Even at this ratio, using wild-type Ad.HSV-tk transduced cells, powerful bystander effects were present with mixtures of cells growing to a tumor size of only 50-75% of that of the nontransduced tumors. However, when Ad.sr39-tk or Ad.dm30-tk transduced cells were used in the cell mixture, significantly more inhibition in tumor size (to about 25% of control size) was obtained. Our results are similar in magnitude to those reported in stably transduced C6 cell lines injected into nude mice. 29, 30 In addition, we expanded these findings to include a human tumor cell line (I-45) growing in SCID mice and a murine tumor cell line (EJ62) growing in a syngeneic immunocompetent Balb/C mouse.
Our most important studies relate to the use of the Ad.tk vectors in clinically relevant tumor models. In these studies, vector was directly injected into established tumor nodules followed by systemic treatment with GCV. As shown in Figure 4 , single injections of 10 9 PFU of either Ad.dm30-tk or Ad.sr39-tk were clearly superior in reducing tumor growth compared to wild-type Ad.HSVtk in small C6 tumors, large C6 tumors or in human I-45 mesothelioma tumors. These studies indicate that adenoviruses encoding the mutant HSV-TK enzymes are likely to yield superior responses in the clinical setting. These results support and expand the observations of Pantuck et al 33 , who also saw enhanced inhibition of tumor growth (in a human prostate carcinoma cell line) after injection of Ad.CMV sr 39 versus Ad.CMV-wild-type tk. Our results are also consistent with the recent report from Gambhir et al 38 , showing that sr39-tk was superior to wild-type tk when used for imaging reporter gene expression using positron emission tomography (PET) imaging.
Which mutant might be the most useful for development for clinical trials? In the in vitro screen, sr39-TK seemed to result in somewhat better sensitivity to GCV (average 2.6-fold decrease IC 50 versus 2.3-fold for dm30-TK- Table 1 ). In the animal experiments, where pretransduced tumor cells were injected, the dm30 vector seemed to be slightly better (see Fig. 3 ), while in the treatment of established tumors, sr39-TK mutant seemed superior. In the Pantuck study, 33 the performance of an Ad.CMV-dm30 vector was inferior to that of wild-type tk or sr39-tk. These data, plus the potential value of Ad.sr39-tk with the prodrug ACV (see below) suggest that this mutant is probably the most promising for further development.
Our results have a number of potentially important clinical implications. First, in terms of safety, equivalent antitumor effects could be expected at lower viral and/or GCV doses when using the mutant viruses compared to wild-type. However, since the goal in future clinical trials is to enhance the relatively weak currently observed effects, the main value of the mutant vectors would be their use at the highest tolerated doses of both virus and GCV to obtain enhanced tumor killing ability. One caveat that needs to be explored would be the potential enhanced toxicity seen with the use of the enhanced mutants. Although this is possible, especially where high levels of liver transduction would be expected, in our intrapleural mesothelioma clinical trials, most of the toxicity we observed was from acute (innate immune) responses to the instillation of virus, 6 ,17 a response that would not be expected to be different in studies using adenoviruses expressing the mutant vectors. The use of vectors with tumor selective promoters would also reduce this potential source of toxicity.
A second interesting issue relates to the potential use of other prodrugs in conjunction with the mutant tks. Although ACV is less immunosuppressive, better tolerated clinically, and can be given in oral form, it has not been used with HSV-tk in gene therapy primarily because of the very high K m the enzyme displays towards the prodrug. This high K m results in the overall susceptibility for ACV-mediated cell killing being almost 100-fold lower than for GCV, based on the ratio of specificity constants. However, as predicted by enzyme kinetic studies, ACVmediated cell killing with dm30-tk and sr39-tk improved 300 to 2000-fold, respectively. Although we did not focus on the use of ACV with the Ad.HSV-tk mutants, in one experiment in C6 cells (Fig 2b) , we did show that cells infected with the Ad.sr39tk mutant had IC 50 values less than 0.2 mM ACV, more than one log lower than cells transduced with wild-type Ad.HSV-tk. Previous in vitro studies in stably infected cell lines 29, 30 and the in vitro studies in a prostate cancer model 33 confirm these findings. These favorable results suggest that further studies should be undertaken to assess the efficacy of the Ad.sr39-tk in the context of ACV or other prodrugs (i.e. penciclovir). Finally, in studies where imaging of gene transfer is attempted (see above), the use of the new mutants would enhance sensitivity.
In summary, we have shown that enhanced HSV-TK mutants can be efficiently transferred to a variety of rodent and human tumor cells using a recombinant adenovirus vector with impressive cytotoxicity following GCV or ACV exposure. The adenovirus-mediated transfer of HSV-tk gene mutants improves prodrug-mediated tumor cell killing compared to wild-type HSV-tk. The effect results in an average two to three-fold decrease in the IC 50 for GCV and both mutant vectors (dm30-tk or sr39-tk) worked fairly equivalently in our models. Importantly, when the mutant vectors are used in animal models of tumor growth, tumor killing is enhanced at least two-fold. Marked enhancement to ACV sensitivity was also seen. Given these markedly improved therapeutic effects at equivalent doses of vector, we suggest that future cancer gene therapy trials using tk suicide gene therapy approaches use vectors encoding enhanced mutants such as sr39-tk.
